相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AhR and Cancer: From Gene Profiling to Targeted Therapy
Anais Paris et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies
Delphine Leclerc et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Discovery of a novel selective water-soluble SMAD3 inhibitor as an antitumor agent
Nannan Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Luis Felipe Campesato et al.
NATURE COMMUNICATIONS (2020)
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
Fiona M. Behan et al.
NATURE (2019)
Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
Xue Bai et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
SMAD signaling promotes melanoma metastasis independently of phenotype switching
Eylul Tuncer et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Phosphorylation status at Smad3 linker region modulates transforming growth factor-β-induced epithelial-mesenchymal transition and cancer progression
Akira Ooshima et al.
CANCER SCIENCE (2019)
Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
Jane Antony et al.
PHYSICAL BIOLOGY (2019)
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
Jennifer Tsoi et al.
CANCER CELL (2018)
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow et al.
CELL (2018)
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Andrew D. Redfern et al.
CLINICAL & EXPERIMENTAL METASTASIS (2018)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
Ali Talebi et al.
NATURE COMMUNICATIONS (2018)
TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition
Anassuya Ramachandran et al.
ELIFE (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018)
Matthew H. Bailey et al.
CELL (2018)
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
Sabrina Rizzolio et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Codon-specific translation reprogramming promotes resistance to targeted therapy
Francesca Rapino et al.
NATURE (2018)
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
Kendall R. Sanson et al.
NATURE COMMUNICATIONS (2018)
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
Ankur Chakravarthy et al.
NATURE COMMUNICATIONS (2018)
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
Sebastien Corre et al.
NATURE COMMUNICATIONS (2018)
A Novel Transforming Growth Factor Beta-Induced Long Noncoding RNA Promotes an Inflammatory Microenvironment in Human Intrahepatic Cholangiocarcinoma
Aude Merdrignac et al.
HEPATOLOGY COMMUNICATIONS (2018)
Genome-wide mapping and analysis of aryl hydrocarbon receptor (AHR)- and aryl hydrocarbon receptor repressor (AHRR)-binding sites in human breast cancer cells
Sunny Y. Yang et al.
ARCHIVES OF TOXICOLOGY (2018)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan et al.
NATURE (2017)
A non-coding function of TYRP1 mRNA promotes melanoma growth
David Gilot et al.
NATURE CELL BIOLOGY (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Xun Jin et al.
NATURE MEDICINE (2017)
SCENIC: single-cell regulatory network inference and clustering
Sara Aibar et al.
NATURE METHODS (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development
Patrick Ming-Kuen Tang et al.
NATURE COMMUNICATIONS (2017)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu et al.
NATURE COMMUNICATIONS (2017)
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song et al.
CANCER DISCOVERY (2017)
A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells
Yoko Chihara et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Dany Nassar et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
Michael P. Smith et al.
CANCER CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Sarah J. Welsh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Melanoma addiction to the long non-coding RNA SAMMSON
Eleonora Leucci et al.
NATURE (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Bjoern Titz et al.
CELL DISCOVERY (2016)
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Jordan Anaya
PEERJ COMPUTER SCIENCE (2016)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
High-throughput functional genomics using CRISPR-Cas9
Ophir Shalem et al.
NATURE REVIEWS GENETICS (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Annelien Verfaillie et al.
NATURE COMMUNICATIONS (2015)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale et al.
SCIENCE SIGNALING (2015)
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Jordi Rodon et al.
INVESTIGATIONAL NEW DRUGS (2015)
Signaling in fibrosis: TGF-beta, wNT, and YAP/TAZ converge
Bram Piersma et al.
FRONTIERS IN MEDICINE (2015)
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
Gianluigi Giannelli et al.
CANCER RESEARCH (2014)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma
Flore Nallet-Staub et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Oncogenic roles of EMT-inducing transcription factors
Alain Puisieux et al.
NATURE CELL BIOLOGY (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Advanced Heat Map and Clustering Analysis Using Heatmap3
Shilin Zhao et al.
BIOMED RESEARCH INTERNATIONAL (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Clemens Krepler et al.
CLINICAL CANCER RESEARCH (2013)
Resistance to BRAF-targeted therapy in melanoma
Ryan J. Sullivan et al.
EUROPEAN JOURNAL OF CANCER (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
Makiko Fujii et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
John M. Lamar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
High-Resolution Genome-wide Mapping of AHR and ARNT Binding Sites by ChIP-Seq
Raymond Lo et al.
TOXICOLOGICAL SCIENCES (2012)
Senescent cells develop a PARP-1 and nuclear factor-κB-associated secretome (PNAS)
Mickael Ohanna et al.
GENES & DEVELOPMENT (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
Franziska van Zijl et al.
MOLECULAR CANCER THERAPEUTICS (2011)
RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity
David Gilot et al.
PLOS ONE (2011)
Cancer stem cells versus phenotype-switching in melanoma
Keith S. Hoek et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis
Delphine Javelaud et al.
CANCER RESEARCH (2007)
Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression
M Jinnin et al.
MOLECULAR PHARMACOLOGY (2006)
MITF: master regulator of melanocyte development and melanoma oncogene
Carmit Levy et al.
TRENDS IN MOLECULAR MEDICINE (2006)
分享论文
